The shares of Adamas Pharmaceuticals, Inc. (NASDAQ:ADMS) currently has mean rating of 1.89 while 1 analysts have recommended the shares as “BUY”, 8 recommended as “OUTPERFORM” and 0 recommended as “HOLD”. The rating score is on a scale of 1 to 5 where 1 stands for strong buy and 5 stands for sell.
The company’s mean estimate for sales for the current quarter ending Jun 16 is 210.00K by 7 analysts. The means estimate of sales for the year ending Dec-15 is 730.00K by 9 analysts.
The mean price target for the shares of Adamas Pharmaceuticals, Inc. (ADMS) is at 35.56 while the highest price target suggested by the analysts is 45.00 and low price target is 22.00. The mean price target is calculated keeping in view the consensus of 9 brokerage firms.
The average estimate of EPS for the current fiscal quarter for Adamas Pharmaceuticals, Inc. (ADMS) stands at -0.70 while the EPS for the current year is fixed at -3.09 by 9 analysts.
The next one year’s EPS estimate is set at -2.69 by 8 analysts while a year ago the analysts suggested the company’s EPS at -3.09. The analysts also projected the company’s long-term growth at 79.36% for the upcoming five years.
In its latest quarter ended on 31st March 2016, Adamas Pharmaceuticals, Inc. (ADMS) reported earnings of $-0.65. The posted earnings topped the analyst’s consensus by $0.11 with the surprise factor of 14.50%. In the matter of earnings surprises, the term “Cockroach Effect” is often implied. Cockroach Effect is a market theory that suggests that when a company reveals bad news to the public, there may be many more related negative events that have yet to be revealed. In the case of earnings surprises, if a company is suggesting a negative earnings surprise it means there are more to come.
On June 22, 2016 Adamas Pharmaceuticals, Inc. (ADMS) announced additional data from its Phase 3 clinical program of ADS-5102 (amantadine HCl) extended-release capsules for the treatment of levodopa-induced dyskinesia (LID) associated with Parkinson’s disease (PD) at the 20th Annual International Congress of Parkinson’s and Movement Disorders in Berlin, Germany. Data was presented from two trials — EASE LID and EASE LID 2 — by Rajesh Pahwa, M.D., a recognized expert in PD and LID. Levodopa-induced dyskinesia, which is a condition characterized by involuntary movements without purpose, can become severely disabling, rendering people with Parkinson’s disease unable to perform routine daily tasks.